Comparative Evaluation of Systemic Inflammatory Indices in Bronchiectasis: Identification of Exacerbation Phenotype
Life · 04.06.2026 · 16 (6) · 949
DOI: 10.3390/life16060949 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life, online erschienen am 04.06.2026. Verfasst von Selda Günaydın und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chest Diseases, Giresun University Faculty of Medicine, Giresun 28100, Türkiye. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Bronchiectasis is a heterogeneous chronic inflammatory airway disease characterized by recurrent exacerbations. Data on composite inflammatory biomarkers for assessing disease activity remain limited.
Methods
This retrospective study included 97 patients with non-cystic fibrosis bronchiectasis categorized as stable (n = 39) or with exacerbated bronchiectasis (n = 58). Demographic, clinical, and laboratory data were analyzed, and inflammatory indices—NLR (neutrophil–lymphocyte ratio), PLR (platelet–lymphocyte ratio), SII (Systemic Immune-Inflammation Index), PIV (Pan-Immune-Inflammation Value), CAR (C-reactive protein-to-albumin ratio), and HALP score (hemoglobin × albumin × lymphocyte/platelet)—were calculated, followed by multivariate logistic regression and ROC analyses.
Results
Patients with bronchiectasis exacerbations had a higher NLR, PLR, PIV, SII, and CAR and lower HALP (all p < 0.001). The C-reactive protein-to-albumin ratio demonstrated the highest discriminative ability (AUC = 0.995), followed by SII and NLR, while lower HALP and SII were independent predictors of exacerbation. The C-reactive protein-to-albumin and sedimentation-to-albumin ratios were strongly correlated with hospitalization duration (both p < 0.001).
Conclusions
Composite inflammatory indices are strongly associated with disease activity in bronchiectasis. CAR showed excellent discriminative performance, while HALP and SII independently predicted exacerbation. These simple, cost-effective biomarkers may support risk stratification and clinical monitoring in routine practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chest Diseases, Giresun University Faculty of Medicine, Giresun 28100, Türkiye.
ORCID-Profile: Selda Günaydın, Hayriye Bektaş Aksoy
Zitieren
APA
Günaydın, S., Aksoy, H. B., & Şimşek, Ş. M. (2026). Comparative Evaluation of Systemic Inflammatory Indices in Bronchiectasis: Identification of Exacerbation Phenotype. Life, 16(6), 949. https://doi.org/10.3390/life16060949
Vancouver
Günaydın S, Aksoy HB, Şimşek ŞM. Comparative Evaluation of Systemic Inflammatory Indices in Bronchiectasis: Identification of Exacerbation Phenotype. Life. 2026;16(6):949. doi:10.3390/life16060949
BibTeX
@article{Gnaydn2026,
author = {Günaydın, Selda and Aksoy, Hayriye Bektaş and Şimşek, Şaban Melih},
title = {Comparative Evaluation of Systemic Inflammatory Indices in Bronchiectasis: Identification of Exacerbation Phenotype},
journal = {Life},
year = {2026},
volume = {16},
number = {6},
pages = {949},
doi = {10.3390/life16060949}
}
EUVIMED